Brokerages Set Baxter International Inc (BAX) Target Price at $75.62
Shares of Baxter International Inc (NYSE:BAX) have been assigned an average rating of “Buy” from the sixteen research firms that are presently covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $75.62.
Several analysts have issued reports on the stock. Zacks Investment Research lowered shares of Baxter International from a “buy” rating to a “hold” rating in a research report on Thursday, May 31st. JPMorgan Chase & Co. upped their price target on shares of Baxter International from $80.00 to $85.00 and gave the stock an “overweight” rating in a research report on Friday, July 27th. Citigroup upped their price target on shares of Baxter International from $74.00 to $76.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 31st. Bank of America upped their price target on shares of Baxter International from $73.00 to $83.00 and gave the stock a “buy” rating in a research report on Tuesday, May 22nd. Finally, Piper Jaffray Companies assumed coverage on shares of Baxter International in a research report on Thursday, May 17th. They set an “overweight” rating and a $77.00 price target on the stock.
In other news, Director Carole J. Shapazian sold 5,400 shares of the stock in a transaction dated Wednesday, August 8th. The shares were sold at an average price of $72.97, for a total value of $394,038.00. Following the transaction, the director now directly owns 15,248 shares of the company’s stock, valued at $1,112,646.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Carole J. Shapazian sold 6,594 shares of the stock in a transaction dated Tuesday, May 22nd. The shares were sold at an average price of $71.79, for a total transaction of $473,383.26. Following the completion of the transaction, the director now directly owns 16,442 shares in the company, valued at $1,180,371.18. The disclosure for this sale can be found here. Insiders sold 94,877 shares of company stock worth $6,880,155 over the last three months. Insiders own 0.07% of the company’s stock.
Shares of BAX stock traded down $0.79 during trading on Wednesday, reaching $70.71. The company’s stock had a trading volume of 1,936,300 shares, compared to its average volume of 3,092,013. The company has a quick ratio of 2.03, a current ratio of 2.62 and a debt-to-equity ratio of 0.39. The firm has a market cap of $38.20 billion, a PE ratio of 28.95, a P/E/G ratio of 1.79 and a beta of 0.77. Baxter International has a one year low of $60.06 and a one year high of $76.51.
Baxter International (NYSE:BAX) last posted its quarterly earnings results on Thursday, July 26th. The medical instruments supplier reported $0.77 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.71 by $0.06. Baxter International had a net margin of 8.29% and a return on equity of 16.63%. The firm had revenue of $2.84 billion for the quarter, compared to analyst estimates of $2.83 billion. During the same period in the prior year, the firm posted $0.63 earnings per share. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. equities analysts predict that Baxter International will post 2.98 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, October 1st. Stockholders of record on Friday, August 31st will be given a $0.19 dividend. This represents a $0.76 annualized dividend and a dividend yield of 1.07%. The ex-dividend date of this dividend is Thursday, August 30th. Baxter International’s payout ratio is presently 30.65%.
Baxter International Company Profile
Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Featured Article: Are Wall Street analysts’ stock ratings worth following?
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.